Effect of @entity14319 on XXXX and intra-uterine growth retardation in primigravidas.

@entity1592 @entity1 @entity1468 @entity14319
OBJECTIVES: To observe the effect of the antioxidant @entity14319 on the occurrence of @entity1468 and @entity1592 in primigravida @entity1 . METHODS: A total of 251 primigravida @entity1 were enrolled in this prospective, randomized controlled study in the second trimester. A total of 116 @entity1 were given oral @entity14319 (Group I) in a dose of 2 mg twice daily while 135 @entity1 were given a placebo (Group II) in the same dose until delivery. The criteria for recruitment included gestational age of 16-20 weeks, singleton pregnancy, absence of any medical complication and willingness on the part of the @entity1 to participate in the study. The @entity1 were followed-up until delivery for development of @entity1468 , mode of delivery and fetal outcome. RESULTS: The two groups were comparable in their maternal characteristics. @entity1468 developed in significantly less @entity1 in the @entity14319 group than in the placebo group (8.6% vs. 17.7%, P=0.043 by chi-square test). Mean diastolic blood pressure was significantly higher in the placebo group (92.2+/-5.98 mmHg vs. 86.7+/-3.80 mmHg, P=0.012). Mean fetal weight was significantly higher in the @entity14319 group (2751.17+/-315.76 g vs. 2657+/-444.30 g, P=0.049). The incidence of @entity1592 was significantly lower in the @entity14319 group than in the placebo group (12% vs. 23.7%, P=0.033). CONCLUSIONS: The results of the present study suggest that the antioxidant @entity14319 reduces the development of @entity1468 and @entity1592 in primigravida @entity1 .
